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Dear Editor,
Predicting recovery of renal function
in patients with acute kidney injury
(AKI) supported with renal replace-
ment therapy (RRT) is one of the top
ten questions in the ﬁeld of current
AKI research. However, deﬁning
renal recovery and accordingly the
best time for discontinuation of RRT
is difﬁcult, as reliable biomarkers are
lacking.
The Beginning and Ending Sup-
portive Therapy for the Kidney
(BEST Kidney) study identiﬁed urine
production ([500 mL/24 h) as the
best predictor for successful discon-
tinuationofRRT[areaunderthecurve
(AUC) 0.81] in contrast to serum
creatinine(SCr,AUC0.64);however,
its predictive value is severely con-
founded by the use of diuretics [1].
Neutrophil gelatinase-associated
lipocalin (NGAL), a 25-kDa protein
involved in iron transportation, is a
potential tool for determination of
initiation of RRT [2, 3]. However,
once a patient is initiated on RRT, it
remains to be elucidated how plasma
NGAL concentrations will change.
To determine plasma NGAL
clearance and sieving coefﬁcient
(SQ) during continuous RRT
(CRRT), we measured preﬁlter and
efﬂuent NGAL concentrations in
three subjects after informed consent
was obtained. Patients were hemoﬁl-
tered with zero ﬂuid balance, 2 L
postdilution mode in continuous
veno-venous hemoﬁltration. Blood
ﬂow was set at 200 mL/min, and
regional citrate anticoagulation was
used. The ﬁlters were ethylene oxide
(ETO)-sterilized Aquamax HF 19
with an in vitro cutoff point of
55 kDa.
NGAL levels were measured using
a research-based enzyme-linked
immunosorbent assay with detection
limit of 10–4,000 ng/mL. NGAL
clearance per minute was estimated
using the assumed stable plasma
concentrations during CRRT over the
ﬁrst 12 h and the calculated amount
Fig. 1 Temporal patterns of the preﬁlter plasma and efﬂuent NGAL concentrations
(ng/ml) in hours after initiation of continuous veno-venous renal replacement therapy in
three individuals with anuric AKI
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SQ was calculated by dividing the
NGAL efﬂuent concentration by the
NGAL preﬁlter plasma concentration.
Three male anuric patients were
studied (age 40–64 years). Their
admission diagnoses were hemor-
rhagic shock, cardiopulmonary
resuscitation, and multitrauma. Base-
line SCr values were 0.57, 0.66, and
0.68 mg/dL,withSCrattimeofCRRT
initiation of 3.7, 9.7, and 12.3 mg/dL.
Estimatedmedian(standarddeviation,
SD) plasma NGAL clearance was 4.8
(1.89) mL/min with median (SD) SQ
of 0.147 (0.04). The preﬁlter and
efﬂuent NGAL concentrations are
plotted against time in Fig. 1.
Normally, plasma NGAL is
cleared through glomerular ﬁltration
and entirely processed by proximal
tubular cells [4]. However, in case of
AKI, plasma concentrations rise
quickly, even when estimated glo-
merular ﬁltration rate (eGFR) is still
normal, and tend to decrease quickly
when the injurious event subsides [5].
Therefore, NGAL might have poten-
tial to be an early indicator of renal
recovery in critically ill patients sup-
ported by RRT.
Our results suggest that plasma
NGAL is hardly cleared during con-
tinuous veno-venous hemoﬁltration.
A possible explanation lies in the fact
that larger serum proteins effectively
lower the passage of small proteins by
forming a gel layer over the mem-
brane pores.
In conclusion, we have shown that
CRRT does not substantially inﬂu-
ence plasma NGAL concentration
and therefore does not need to be
taken into account when kinetics of
plasma NGAL levels are used as an
indicator for persistent renal injury or
renal recovery in hemoﬁltered criti-
cally ill patients.
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